Englewood Lab (A950140) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was $33.95M, up 16% year-over-year, with net income of $4.82M and operating income of $3.82M.

• Gross margin improved to 22.1% from 22.5% in Q1 2025, with EPS at $0.24, up from $0.11 year-over-year.

• The company maintains a strong cash position with $31.3M in cash and cash equivalents.

Financial highlights

• Q1 2026 revenue: $33.95M (Q1 2025: $29.28M); net income: $4.82M (Q1 2025: $2.23M).

• Operating income: $3.82M (Q1 2025: $3.15M); gross profit: $7.52M (Q1 2025: $6.59M).

• Cash flow from operations: $5.99M; free cash flow: $7.17M.

• Dividend payout for Q1: $2.8M.

Outlook and guidance

• The company plans to focus on expanding in the premium skincare market and targeting global top-tier brands.

• Continued investment in R&D and production capacity to support growth.